Evidence map›Paper›PMID 41775992›Full record

ArticleThe AAPS journal2026

In-depth Evaluation of the Olink Target 48 Cytokine Panel: Inter-Laboratory Evaluation of Performance and Reliability for Biomarker Studies in Oncology.

Yuhong Xiang, Chris Beaver, Zhenqiang Su, Dave Yeung, Jiejin Chen, Bin Li, Shawn Ciotti, Heather Myler

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuhong XiangTranslational Biomarkers and Bioanalytics, Takeda Pharmaceutical Company Ltd, 35 Landsdowne St, Cambridge, Massachusetts, 02139, USA.ORCID 0009-0001-3023-257X
Chris BeaverTranslational Biomarkers and Bioanalytics, Takeda Pharmaceutical Company Ltd, 35 Landsdowne St, Cambridge, Massachusetts, 02139, USA.ORCID 0000-0003-2468-5422
Zhenqiang SuTranslational Biomarkers and Bioanalytics, Takeda Pharmaceutical Company Ltd, 35 Landsdowne St, Cambridge, Massachusetts, 02139, USA.ORCID 0009-0002-0846-1170
Dave YeungTranslational Biomarkers and Bioanalytics, Takeda Pharmaceutical Company Ltd, 35 Landsdowne St, Cambridge, Massachusetts, 02139, USA.ORCID 0009-0001-1974-2325
Jiejin ChenTranslational Biomarkers and Bioanalytics, Takeda Pharmaceutical Company Ltd, 35 Landsdowne St, Cambridge, Massachusetts, 02139, USA.ORCID 0009-0003-3935-7509
Bin LiTranslational Biomarkers and Bioanalytics, Takeda Pharmaceutical Company Ltd, 35 Landsdowne St, Cambridge, Massachusetts, 02139, USA.ORCID 0000-0002-3419-5665
Shawn CiottiTranslational Biomarkers and Bioanalytics, Takeda Pharmaceutical Company Ltd, 35 Landsdowne St, Cambridge, Massachusetts, 02139, USA.ORCID 0009-0007-2040-8037
Heather MylerTranslational Biomarkers and Bioanalytics, Takeda Pharmaceutical Company Ltd, 35 Landsdowne St, Cambridge, Massachusetts, 02139, USA. heather.myler@takeda.com.ORCID 0009-0004-2725-1659

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Olink Target 48 Cytokine (Thermo Fisher Scientific) is a biomarker panel and assay kit frequently used to characterize the pharmacodynamic effects of novel therapeutics and predict treatment outcomes. We have assessed assay performance across four commercial laboratories to determine the consistency of results. Overall reliability of individual biomarkers and the performance of controls were also assessed, and data were used for an exploratory assessment of differential biomarker expression in patients with head and neck cancer or lung cancer, relative to healthy donors. Reproducibility between operators was found to be good for three of the four laboratories, although the median coefficient of variation between operators for laboratory 4 was above the threshold of acceptability (30%) in the first half of the study. Performance across serial dilutions was also good for all laboratories except laboratory 2. Overall, data were statistically concordant for all laboratories except laboratory 4. Olink sample and calibrator controls performed well, and 43 of the 45 biomarkers in the panel were found to have good or moderate reliability. In total, 21 biomarkers were found to be upregulated or downregulated in patients with cancer relative to healthy donors. This comprehensive evaluation supports the use of Olink Target 48 Cytokine for use in biomarker studies and clinical applications, and highlights the need for standardization in sample handling and assay execution across providers.

Indexed as

Biomarkers, TumorCytokinesHead and Neck NeoplasmsLung NeoplasmsHumansReproducibility of ResultsBiomarkers, TumorCytokinesbiomarkerscytokinesOlinkoncologyproteomics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.